These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 28184031)

  • 1. Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy.
    Prebet T; Toma A; Cluzeau T; Sekeres MA; Vey N; Park S; Al Ali N; Sugrue MM; Komrokji R; Fenaux P; Gore SD
    Oncotarget; 2017 Jun; 8(23):37866-37874. PubMed ID: 28184031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
    Park S; Hamel JF; Toma A; Kelaidi C; Thépot S; Campelo MD; Santini V; Sekeres MA; Balleari E; Kaivers J; Sapena R; Götze K; Müller-Thomas C; Beyne-Rauzy O; Stamatoullas A; Kotsianidis I; Komrokji R; Steensma DP; Fensterl J; Roboz GJ; Bernal T; Ramos F; Calabuig M; Guerci-Bresler A; Bordessoule D; Cony-Makhoul P; Cheze S; Wattel E; Rose C; Vey N; Gioia D; Ferrero D; Gaidano G; Cametti G; Pane F; Sanna A; Germing U; Sanz GF; Dreyfus F; Fenaux P
    J Clin Oncol; 2017 May; 35(14):1591-1597. PubMed ID: 28350519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria.
    Aschauer G; Greil R; Linkesch W; Nösslinger T; Stauder R; Burgstaller S; Fiegl M; Fridrik M; Girschikofsky M; Keil F; Petzer A
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e143-9. PubMed ID: 26422252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.
    Toma A; Kosmider O; Chevret S; Delaunay J; Stamatoullas A; Rose C; Beyne-Rauzy O; Banos A; Guerci-Bresler A; Wickenhauser S; Caillot D; Laribi K; De Renzis B; Bordessoule D; Gardin C; Slama B; Sanhes L; Gruson B; Cony-Makhoul P; Chouffi B; Salanoubat C; Benramdane R; Legros L; Wattel E; Tertian G; Bouabdallah K; Guilhot F; Taksin AL; Cheze S; Maloum K; Nimuboma S; Soussain C; Isnard F; Gyan E; Petit R; Lejeune J; Sardnal V; Renneville A; Preudhomme C; Fontenay M; Fenaux P; Dreyfus F
    Leukemia; 2016 Apr; 30(4):897-905. PubMed ID: 26500139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion.
    Sánchez-García J; Del Cañizo C; Lorenzo I; Nomdedeu B; Luño E; de Paz R; Xicoy B; Valcárcel D; Brunet S; Marco-Betes V; García-Pintos M; Osorio S; Tormo M; Bailén A; Cerveró C; Ramos F; Diez-Campelo M; Such E; Arrizabalaga B; Azaceta G; Bargay J; Arilla MJ; Falantes J; Serrano-López J; Sanz GF;
    Br J Haematol; 2014 Jul; 166(2):189-201. PubMed ID: 24716538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine.
    Zeidan AM; Al Ali NH; Padron E; Lancet J; List A; Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):705-10. PubMed ID: 26440749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents.
    Sibon D; Cannas G; Baracco F; Prebet T; Vey N; Banos A; Besson C; Corm S; Blanc M; Slama B; Perrier H; Fenaux P; Wattel E;
    Br J Haematol; 2012 Mar; 156(5):619-25. PubMed ID: 22211483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide performance in the real world: patterns of use and effectiveness in a Medicare population with myelodysplastic syndromes.
    Zeidan AM; Gore SD; McNally DL; Baer MR; Hendrick F; Mahmoud D; Davidoff AJ
    Cancer; 2013 Nov; 119(21):3870-8. PubMed ID: 23922173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy.
    Oliva EN; Latagliata R; Laganà C; Breccia M; Galimberti S; Morabito F; Poloni A; Balleari E; Cortelezzi A; Palumbo G; Sanpaolo G; Volpe A; Specchia G; Finelli C; D'Errigo MG; Rodà F; Alati C; Alimena G; Nobile F; Aloe Spiriti MA
    Leuk Lymphoma; 2013 Nov; 54(11):2458-65. PubMed ID: 23432724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes.
    Giagounidis A; Mufti GJ; Fenaux P; Germing U; List A; MacBeth KJ
    Ann Hematol; 2014 Jan; 93(1):1-11. PubMed ID: 24018623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis.
    Rojas SM; Díez-Campelo M; Luño E; Cabrero M; Pedro C; Calabuig M; Nomdedeu B; Cedena T; Arrizabalaga B; García M; Cerveró C; Collado R; Azaceta G; Ardanaz MT; Muñoz JA; Xicoy B; Rodríguez MJ; Bargay J; Morell MJ; Simiele A; del Cañizo C
    Leuk Res; 2014 Mar; 38(3):304-9. PubMed ID: 24333115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenalidomide treatment induced the normalization of marker protein levels in blood plasma of patients with 5q-myelodysplastic syndrome.
    Messingerová L; Jonášová A; Barančik M; Poleková L; Šereš M; Gibalová L; Breier A; Sulová Z
    Gen Physiol Biophys; 2015 Oct; 34(4):399-406. PubMed ID: 26001289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenalidomide: a review of its use in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with 5q chromosome deletion.
    Syed YY; Scott LJ
    Drugs; 2013 Jul; 73(11):1183-96. PubMed ID: 23824699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic neoplasm: a HARMONY Alliance study.
    Crisà E; Mora E; Germing U; Bally C; Diez Campelo M; Myllymäki M; Jädersten M; Komrokji R; Platzbecker U; Haase D; Hofmann WK; Al Ali NH; Barraco D; Bargay JJ; Bernal T; López Cadenas F; Calvisi A; Capodanno I; Cerrano M; Ciancia R; Crugnola M; Kündgen A; Finelli C; Fozza C; Frairia C; Freja E; Ganster C; Kubasch AS; Jimenez MJ; Latagliata R; Hernandez Mohedo F; Molero A; Vara Pampliega M; Perez CA; Pietrantuono G; Poloni A; Pomares H; Recasens V; Rüfer A; Signori A; Hellstrom-Lindberg E; Fenaux P; Sanz G; Santini V
    Leukemia; 2024 Oct; 38(10):2259-2265. PubMed ID: 39103678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide.
    Sugimoto Y; Sekeres MA; Makishima H; Traina F; Visconte V; Jankowska A; Jerez A; Szpurka H; O'Keefe CL; Guinta K; Afable M; Tiu R; McGraw KL; List AF; Maciejewski J
    J Hematol Oncol; 2012 Mar; 5():4. PubMed ID: 22390313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence.
    Oliva EN; Lauseker M; Aloe Spiriti MA; Poloni A; Cortelezzi A; Palumbo GA; Balleari E; Sanpaolo G; Volpe A; Ricco A; Ronco F; Alati C; D'Errigo MG; Santacaterina I; Kündgen A; Germing U; Latagliata R
    Cancer Med; 2015 Dec; 4(12):1789-97. PubMed ID: 26376955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low RPS14 expression in MDS without 5q - aberration confers higher apoptosis rate of nucleated erythrocytes and predicts prolonged survival and possible response to lenalidomide in lower risk non-5q- patients.
    Wu L; Li X; Xu F; Zhang Z; Chang C; He Q
    Eur J Haematol; 2013 Jun; 90(6):486-93. PubMed ID: 23506134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q).
    Butrym A; Lech-Maranda E; Patkowska E; Kumiega B; Bieniaszewska M; Mital A; Madry K; Torosian T; Wichary R; Rybka J; Warzocha K; Mazur G
    BMC Cancer; 2015 Jul; 15():508. PubMed ID: 26152663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulating drugs in myelodysplastic syndromes.
    Adès L; Fenaux P
    Hematology Am Soc Hematol Educ Program; 2011; 2011():556-60. PubMed ID: 22160089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial.
    Braulke F; Schulz X; Germing U; Schuler E; Platzbecker U; Nolte F; Hofmann WK; Giagounidis A; Götze K; Lübbert M; Schlenk RF; Schanz J; Bacher U; Ganser A; Büsche G; Letsch A; Schafhausen P; Bug G; Brümmendorf TH; Haas R; Trümper L; Shirneshan K; Haase D
    Ann Hematol; 2017 Jun; 96(6):887-894. PubMed ID: 28374162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.